Utah Medical Products (UTMD) Q1 2025 earnings summary

Executive summary

• Net sales for Q1 2025 were $9.71M, down 14.4% year-over-year, mainly due to a $1.5M decline in OEM sales to PendoTECH, which accounted for 91% of the revenue drop.

• Net income fell 23.1% to $3.04M, with EPS down 16% to $0.92, cushioned by share repurchases reducing diluted shares outstanding.

• Gross profit margin declined to 57.0% from 59.7% due to lower sales and less absorption of fixed manufacturing overhead.

• Operating income margin was 32.5%, down from 34.2%, with lower litigation expenses partially offsetting the impact of lower sales.

• Domestic direct sales increased, but were offset by sharp declines in OEM and international sales.

Financial highlights

• Revenue: $9.71M (down 14.4% year-over-year); domestic sales down 9.8%, OUS sales down 19.8%.

• Net income: $3.04M (down 23.1% year-over-year); net income margin 31.3%.

• EPS (diluted): $0.92 (down 16% year-over-year); 3.3M diluted shares.

• Gross profit: $5.54M (down 18.1%); gross margin 57.0%.

• Operating income: $3.15M (down 18.8%); operating margin 32.5%.

• EBITDA (adjusted): $4.7M (down from $5.5M); trailing twelve-month EBITDA $19.0M.

Outlook and guidance

• Management expects most of the projected 2025 revenue decline from PendoTECH to have already occurred.

• Revenue and gross margin for the remainder of 2025 are expected to be consistent with Q1 levels.

• Adjusted EBITDA for 2025 is targeted at $18M, supported by a trailing twelve-month EBITDA of $18.96M as of March 31, 2025.

• Objectives include leveraging biopharma transducer opportunities, OUS integration, defending Filshie Clip, and pursuing accretive acquisitions.

• Potential negative impact from geopolitical tariffs, especially regarding China, could affect future quarters.